Barclays raised the firm’s price target on Neurocrine (NBIX) to $165 from $160 and keeps an Overweight rating on the shares. The firm says Crenessity pricing is above expectations. It expects congenital adrenal hyperplasia sales estimates to be revised higher and looks for early indicators of uptake while the longer-term narrative develops.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio